Efficacy and toxicity profile of eribulin mesylate for metastatic breast cancer (MBC) patients (pts) in the routine clinic: A French observational study.
Anne Patsouris
No relevant relationships to disclose
Benjamin Linot
No relevant relationships to disclose
Marie Robert
No relevant relationships to disclose
Carole Gourmelon
No relevant relationships to disclose
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; SERVIER
Angelique Brunot
No relevant relationships to disclose
Claudia Lefeuvre-Plesse
Honoraria - Eisai
Jerome Martin
No relevant relationships to disclose
Adele Marquis
No relevant relationships to disclose
Hugues Pierre Bourgeois
No relevant relationships to disclose
Mickael Som
No relevant relationships to disclose
Herve Desclos
Honoraria - Eisai
Olivier Tredan
Research Funding - Eisai